A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
Primary Extra-cranial Solid Tumor|Recurrent or Refractory Glypican 3 (GPC3)
DRUG: Codrituzumab
estimate the MTD, The Phase A dose escalation scheme will follow a 3+3 design., 1 year
response rate, partial + complete response according to RECIST v1.1), at 6 weeks
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.